RGN-259

Korean stock market Record $259 bn yet to find investment targets in South Korea

South Koreans parked a record 350 trillion won ($259 billion) in cash-equivalents such as money market funds (MMFs) as they failed to find investmen...

Bio & Pharma HLB starts Phase 3 clinical trials for ophthalmic disease treatment in US

South Korea's pharmaceutical company HLB Therapeutics Co. announced on Thursday that it has started patient administration of "RGN-259," a treatment...

Bio & Pharma HLB confirms ophthalmic disease treatment in phase 3 clinical trials

South Korea’s biomedicine startup HLB Therapeutics Co. said on Monday that its Neurotrophic Keratopathy (NK) treatment RGN-259 proved effectiv...